|
|
Article: Alfacell Presents Encouraging Data From Onconase Studies.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alfacell Corp. presented in vivo and in vitro data showing Onconase inhibits tumor growth of non-small-cell lung cancer and breast cancer cells.
A poster presentation at the annual meeting of the American Association for Cancer Research in Los Angeles demonstrated Onconase significantly inhibited tumor growth by inducing apoptosis in A549 and NCI-H1975 human NSCLC cells, and MDA-MB-231 and MCF-7 human breast cancer cells, without damaging noncancerous cells such as HLF-1 human lung fibroblast and NCI/3T3 fibroblast. Data also indicated twice weekly injections were more effective than an equivalent single-dose injection in those tumor types.
Onconase ...
Related newspaper, magazine, and journal articles:
|
|
Article: Pain Therapeutics Announces Fourth Quarter and Year End 2004 ...
PR Newswire;
January 26, 2005 ;
700+ words
... ... We ended the year with three drugs in Phase III clinical trials, nearly $100 million ... results now set the stage for a series of Phase III clinical announcements in 2005. After ... look forward to unblinding data from our Phase III trials and announcing clinical results ...
|
|